Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: a review
PA Thompson, DE Wright, CE Counsell… - International …, 2012 - cambridge.org
PA Thompson, DE Wright, CE Counsell, J Zajicek
International psychogeriatrics, 2012•cambridge.orgBackground: The social and economic burden of Alzheimer's disease (AD) and its
increasing prevalence has led to much work on new treatment strategies and clinical trials.
The search for surrogate markers of disease progression continues but traditional parallel
group trial designs that use well-established, but often insensitive, clinical outcome
measures predominate. Methods: We performed a systematic search across the Cochrane
Library and PubMed abstracts published between January 2004 and August 2009 …
increasing prevalence has led to much work on new treatment strategies and clinical trials.
The search for surrogate markers of disease progression continues but traditional parallel
group trial designs that use well-established, but often insensitive, clinical outcome
measures predominate. Methods: We performed a systematic search across the Cochrane
Library and PubMed abstracts published between January 2004 and August 2009 …
Background
The social and economic burden of Alzheimer's disease (AD) and its increasing prevalence has led to much work on new treatment strategies and clinical trials. The search for surrogate markers of disease progression continues but traditional parallel group trial designs that use well-established, but often insensitive, clinical outcome measures predominate.
Methods
We performed a systematic search across the Cochrane Library and PubMed abstracts published between January 2004 and August 2009. Information regarding the clinical trial methodology, outcome measures, intervention type and primary statistical analysis techniques was extracted and categorized, according to a standard protocol.
Results
We identified 149 papers describing results from clinical trials in AD containing sufficient detail for our purposes. The largest proportion (38%) presented results of trials based on tests of cognition as the primary outcome measure. The primary analysis in most papers (85%) was a univariate significance test of a single primary outcome measure.
Conclusions
The majority of trials reported a comparison of baseline and end-point assessment over relatively short patient follow-up periods, using univariate statistical methods to compare differences between intervention and control groups in the primary analysis. There is considerable scope to introduce newer statistical methods and trial designs in treatment evaluations in AD.
Cambridge University Press以上显示的是最相近的搜索结果。 查看全部搜索结果